title: Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week.
abstract: BACKGROUND
  Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) is characterized by recurrent edema attacks in various organs. The objective of the present study was to assess the efficacy and safety of weekly long-term replacement treatment with one or more injections of plasma-derived C1-INH concentrate per week (WLTC) in patients with HAE-C1-INH.
  
  
  METHODS
  Nineteen patients with HAE-C1-INH underwent WLTC for 9 years on average. The benefits and risks were determined based on regular recording by the patients of the severity and number of attacks at the beginning and the end of the study.
  
  
  RESULTS
  All patients reported that all or most of their attacks were much less severe: the percentage of severe attacks was 93.3% without and 3.8% with treatment. In 8 of the 14 patients undergoing WLTC, the monthly number of attacks was lower at the end of the study than before the study, higher in 5 patients, and unchanged in 1 patient. The mean number of attacks per week in 6 patients (1 patient initially received weekly on-demand treatment for 2 years and then shifted to WLTC) with weekly on-demand treatment was 4.3 (SD 1.9) at the beginning and 8.0 (SD 3.1) at the end of the study.
  
  
  CONCLUSIONS
  HAE-C1-INH can be significantly improved by one or more injections of C1-INH concentrate per week. However, patients have to accept a large number of intravenous injections and, in some cases, an increase in disease activity.
authors.affiliation: Department of Dermatology, Johannes Gutenberg University, Langenbeckstrasse 1, Mainz, Germany. bork@hautklinik.klinik.uni-mainz.de
authors.forename: Konrad
authors.initials: K
authors.lastname: Bork
authors.forename: Jochen
authors.initials: J
authors.lastname: Hardt
mesh_terms: D000328:Adult; D000368:Aged; D054179:Angioedemas, Hereditary / Q000188:drug therapy*; D001920:Bradykinin / Q000008:administration & dosage / Q000031:analogs & derivatives; D065168:Bradykinin Receptor Antagonists; D050718:Complement C1 Inhibitor Protein / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D065168:Bradykinin Receptor Antagonists; D050718:Complement C1 Inhibitor Protein; C065679:icatibant; D001920:Bradykinin